Organogenesis Receives $20M Financing Facility from Eastward Capital Partners

Organogenesis, Inc., a Canton, Mass.-based developer of advanced wound care innovation and technologies, closed a $20m financing facility.

Eastward Capital Partners provided the venture debt financing.

The company intends to use the funds to continue to enhance its product portfolio.

Originally founded as a spin-off from technology developed at MIT in 1985 and led by Gary S. Gillheeney, Sr., President and Chief Executive Officer, Organogenesis offers a portfolio of bioactive and acellular biomaterials products for advanced wound care, orthopedics, and spine.




Join the discussion